Community pharmacists' practices and perspectives on deprescribing high‐risk psychotropic medicines: National survey findings
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70466 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Monica Jung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Psychotropic Drugs, Pharmacists, Community Pharmacy Services, Deprescriptions. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council Investigator, National Health and Medical Research Council.
Abstract (Originalsprache)
Aim
To explore the practices, confidence and perspectives of community pharmacists in deprescribing high‐risk psychotropic medicines, including opioid analgesics, benzodiazepine, gabapentinoids and medicinal cannabis.
Methods
An anonymous, cross‐sectional national online survey was conducted between January and April 2025 among Australian community pharmacists. The survey captured data on pharmacist demographics, their workplace (pharmacy) characteristics, their provision of high‐risk psychotropic medicines, and pharmacists' perspectives, confidence and practices related to implementing strategies to support deprescribing of these medicines. Descriptive statistics and logistic regression analyses were conducted to explore the factors associated with initiating discussions with patients about deprescribing.
Results
The sample comprised of 730 pharmacists, representing approximately 12% of all Australian community pharmacies. Approximately three‐quarters indicated their pharmacy received prescriptions every day for opioids (80.6%), benzodiazepines (75.2%) and gabapentinoids (72.1%), whilst fewer than one‐tenth of pharmacies (8.9%) received medicinal cannabis prescriptions every day. Pharmacists working outside of capital cities (i.e. other urban, rural or remote areas; adjusted odds ratio (aOR): 1.33, 95% confidence intervals (CIs): 0.97–1.83), pharmacy managers/owners (aOR: 1.29, 95% CIs: 1.22–1.50) and those with ≥ 15 years of professional experience (OR: 1.57, 95% CIs: 1.17–2.11) had higher odds of initiating discussions on deprescribing psychotropic medicines compared with those working in capital cities, employee pharmacists and those with
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
ORCID-Profile: Monica Jung, Suzanne Nielsen
Förderung
- National Health and Medical Research Council Investigator
- National Health and Medical Research Council
Zitieren
APA
Jung, M., Picco, L., Langford, A. V., Laing, R., Dostal, J., & Nielsen, S. (2026). Community pharmacists' practices and perspectives on deprescribing high‐risk psychotropic medicines: National survey findings. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70466
Vancouver
Jung M, Picco L, Langford AV, Laing R, Dostal J, Nielsen S. Community pharmacists' practices and perspectives on deprescribing high‐risk psychotropic medicines: National survey findings. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70466
BibTeX
@article{Jung2026,
author = {Jung, Monica and Picco, Louisa and Langford, Aili V and Laing, Rose and Dostal, Jana and Nielsen, Suzanne},
title = {Community pharmacists' practices and perspectives on deprescribing high‐risk psychotropic medicines: National survey findings},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70466}
}
EUVIMED